Please login to the form below

Not currently logged in
Email:
Password:

Qsiva

This page shows the latest Qsiva news and features for those working in and with pharma, biotech and healthcare.

Eisai doubles Belviq's US sales force

Eisai doubles Belviq's US sales force

This followed a knockback for Vivus' drug in October 2012, when regulators refused Qsiva (Vivus' preferred brand name for Europe) due to cardiovascular safety concerns.

Latest news

  • Orexigen files obesity drug in EU Orexigen files obesity drug in EU

    In October 2012, Vivus faced a knockback from the European Medicines Agency (EMA) for obesity treatment Qsiva (phentermine/topiramate ER), despite receiving prior approval in the US. ... Like its rival Qsiva, Belviq is also recommended in the US.

  • Novo Nordisk on track to file liraglutide in obesity Novo Nordisk on track to file liraglutide in obesity

    There is still a long way to go before liraglutide reaches the market, however, and Novo should expect a tough regulatory challenge if the fate of recent obesity treatments Qsymia/ Qsiva

  • CHMP upholds rejection of Vivus' obesity drug CHMP upholds rejection of Vivus' obesity drug

    Still no recommendation for Qsiva in Europe. Vivus faced a major setback yesterday when a European Medicines Agency (EMA) committee upheld its earlier decision to reject the company's obesity drug ... has retained its position and said a cardiovascular

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...